RT Journal
A1 Friedrich MJ
T1 EXperimental malaria vaccine
JF JAMA
JO JAMA
YR 2012
FD December 19
VO 308
IS 23
SP 2449
OP 2449
DO 10.1001/jama.2012.128613
UL http://dx.doi.org/10.1001/jama.2012.128613
AB 
In the phase 3 trial, 6537 infants who were between 6 and 12 months old at the time of the first vaccination received 3 doses of either the RTS,S/AS01 candidate vaccine or a nonmalaria comparator vaccine at 1-month intervals along with standard childhood vaccines. An analysis of the incidence of malaria in infants for 12 months after the third vaccine dose found that the RTS,S/AS01 vaccine reduced the risk of detectable malaria and severe malaria by 31% and 37%, respectively, compared with controls.